Trial Profile

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TERN-601 (Primary)
Indications Obesity
Focus Therapeutic Use
Acronyms FALCON
Sponsors Terns Pharmaceuticals

Most Recent Events

23 Jun 2025 Status changed from recruiting to active, no longer recruiting.
25 Mar 2025 Status changed from not yet recruiting to recruiting.
20 Mar 2025 According to a Terns Pharmaceuticals media release,12-week data expected in the fourth quarter of 2025. Phase 2 titration will range between two to four weeks at each intermediate dose before achieving the target dose.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com